Proteomic test for anti-PD-1 checkpoint blockade treatment of metastatic melanoma with and without BRAF mutations
Abstract The therapeutic landscape in metastatic melanoma has changed dramatically in the last decade, with the success of immune checkpoint inhibitors resulting in durable responses for a large number of patients. For patients with BRAF mutations, combinations of BRAF and MEK inhibitors demonstrate...
Furkejuvvon:
| Váldodahkkit: | , , , , , , , , , , , |
|---|---|
| Materiálatiipa: | Artigo |
| Giella: | Inglês |
| Almmustuhtton: |
BMJ Publishing Group
2019-03-01
|
| Ráidu: | Journal for ImmunoTherapy of Cancer |
| Fáttát: | |
| Liŋkkat: | http://link.springer.com/article/10.1186/s40425-019-0569-1 |
| Fáddágilkorat: |
Eai fáddágilkorat, Lasit vuosttaš fáddágilkora!
|